相关实验视频
Updated: Jul 17, 2025

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.8K
个性化决策,预测皮肤状细胞癌的绝对转移风险:开发和验证临床病理学模型
Barbara Rentroia-Pacheco1, Selin Tokez1, Edo M Bramer1
1Department of Dermatology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
EClinicalMedicine
|September 4, 2023
概括
一个新的模型预测皮肤状细胞癌 (cSCC) 患者的转移风险,改善个性化治疗. 该工具有助于识别高风险cSCC病例,以提供量身定制的护理和随访.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 生物统计学 生物统计学
- 临床信息学 临床信息学
背景情况:
- 皮肤状细胞癌 (cSCC) 是一种流行性皮肤癌,转移率为2-5%.
- 目前的分期系统缺乏绝对转移风险预测,阻碍了个性化治疗策略.
- 准确的风险评估对于优化患者管理和随访协议至关重要.
研究的目的:
- 开发和验证一种临床病理模型,用于预测cSCC患者转移的概率.
- 除了现有的分阶段系统之外,为更精确的风险分层提供一个工具.
- 帮助临床医生识别可能受益于加强监测或辅助治疗的患者.
主要方法:
- 使用来自荷兰和英格兰的全国数据开发了一个嵌套病例控制队列.
- 使用权重考克斯回归与逆向选择来确定关键的临床病理预测因子.
- 使用C指数,校准指标和决策曲线分析验证模型,将其与已建立的分阶段系统进行比较.
主要成果:
- 开发的模型确定了八个重要的临床病理变量.
- 具有强烈的区分能力,乐观度调整后的C指数为0.80 (发展) 和0.84 (验证).
- 与当前的分期系统相比,显示出良好的校准 (斜率为0.96) 和更好的临床实用性,特别是在治疗决策方面.
结论:
- 经验证的模型使用常规数据为cSCC患者提供个性化转移风险预测.
- 这种工具使临床医生能够识别高风险个体,以提供量身定制的护理,治疗和随访.
- 需要进一步调查,以评估该模型在不同患者群体和临床环境中的实用性.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
300
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381